Copy number gain of MET gene with low level in a metastatic lung adenocarcinoma patient represents response to salvage treatment with savolitinib and osimertinib: a case report
We considered that a regimen of savolitinib + osimertinib combination sometimes may still be potentially beneficial for NSCLC patients with low-GCN-level MET amplification. However, it needs further confirmation in a larger cohort.
Authors
- Xinyong Dong (ORCID: https://orcid.org/0000-0002-3445-5455)
- Jianxin Chen (ORCID: https://orcid.org/0000-0001-8519-4462)
- Jian Wang (ORCID: https://orcid.org/0000-0001-5443-2675)
- Yunpeng Liu (ORCID: https://orcid.org/0000-0002-0959-0209)
- Keying Lin
Institutions
- Zhejiang Chinese Medical University (CN)
- Changsha Medical University (CN)
- The Third Affiliated Hospital of Zhejiang Chinese Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-04-29
- DOI
- https://doi.org/10.3389/fonc.2025.1507677
- Citations
- 11
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 16.70
Funders
- Quzhou Municipal Science and Technology Bureau